

	Office of Sponsor and Regulatory Oversight	Document #: 102
	Audit Policy	Revision #: 1
		Effective Date: 30AUG2019

1. Purpose

To establish and describe the Office of Sponsor and Regulatory Oversight (OSRO) Audit policy.

2. Scope

2.1. OSRO in the Center for Cancer Research (CCR), National Cancer Institute (NCI) shall establish and control the policy.

2.2. Investigators, research team members, other departmental personnel, and external NIH collaborators and contractors when they are working on studies conducted under a CCR-held Investigational New Drug (IND) application, Investigational Device Exemption (IDE), or supported by a CCR-held Master File under OSRO oversight shall comply with the policy.

2.3. Limitation

2.3.1. Personnel are not bound to this policy when working on non-IND or IDE studies and/or no interdepartmental collaboration with OSRO as Sponsor is required.

2.3.2. Nothing in this policy will supersede NCI, National Institutes of Health (NIH) or Health and Human Services (HHS) requirements.

3. Responsibilities

3.1. CCR Management is committed to providing resources to meet the requirements for implementing an Audit policy and supporting its continual improvement.

3.2. OSRO personnel are responsible for understanding and using the Audit policy.

3.3. The OSRO Director is responsible for establishing and maintaining OSRO's Audit policy.

3.4. Investigators, research team members, other departmental personnel, and external NIH collaborators and contractors will allow site access to the auditors.

4. References

4.1. ICH E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1) Guidance for Industry (FDA), March 2018

5. Definitions

Refer to the OSRO Lexicon.

6. Policy

6.1. Sponsor Quality Management System Audits

6.1.1. OSRO Quality will conduct periodic audits to assure that the Quality Management System (QMS) and ancillary programs comply with requirements and are following established procedures, and to determine the effectiveness of the Sponsor quality system.

	Office of Sponsor and Regulatory Oversight	Document #: 102
	Audit Policy	Revision #: 1
		Effective Date: 30AUG2019

6.2. Sponsor Vendor Audits

6.2.1. OSRO will establish a vendor audit plan for each product for which OSRO will be considered the manufacturer.

6.2.1.1. OSRO is considered the manufacturer for those products that are:

- 6.2.1.1.1. Included in an OSRO Master File, or
- 6.2.1.1.2. In an IND submission including the complete Chemistry, Manufacturing and Controls (CMC) sections (not reliant on a letter of cross reference, or available commercial product), or
- 6.2.1.1.3. In an IDE submission including the complete manufacturing information (not reliant on a letter of cross reference, or available commercial product).

6.2.2. Audits of product manufacturing vendors may be deferred to the NIH Clinical Center Office of Research Support and Compliance (ORSC), or other NIH entities at the discretion of the OSRO Director.

6.2.3. OSRO will audit contract research organizations, pharmaceutical companies, institutions, service providers and other collaborators, as necessary, to assure that they are following required Quality System requirements.

6.3. Clinical Trial Audits

6.3.1. OSRO will audit the main and ancillary clinical research facilities utilized for clinical trials, investigational product storage or preparation, human subject specimen storage or testing, and endpoint data generation or collection to evaluate compliance with the protocol, OSRO Policy and institutional Standard Operating Procedures (SOPs), Good Clinical Practice (GCP), and applicable regulatory requirements.

6.3.1.1. A clinical site audit could be triggered by a significant and/or pervasive clinical site monitoring finding, but the justification and execution of an audit would be independent of and separate from routine clinical site monitoring.

6.3.2. The audit plan, procedures and prioritization will be guided by the importance of the trial to submissions to regulatory authorities, the type and complexity of the trial, the level of risks to the trial subjects, and any identified problem(s).

6.4. Audits will be conducted in accordance with the written audit plan on what to audit, how to audit, the frequency of audits, and the form and content of audit reports.

6.5. Observations and findings of the auditor will be documented.

6.6. Auditors will be qualified by training and experience to conduct audits.

6.6.1. Auditor qualifications will be documented.

6.7. This Policy shall be reviewed periodically and updated as necessary.

	Office of Sponsor and Regulatory Oversight	Document #: 102
	Audit Policy	Revision #: 1
		Effective Date: 30AUG2019

7. Change Summary

Revision Number	Effective Date	Description of Change
1	30AUG2019	New Document